YILI(SH:600887) 智通财经网·2026-01-07 11:50Group 1 - Yili Co., Ltd. announced that Chairman Pan Gang plans to reduce his holdings by up to 62 million shares, accounting for 0.98% of the company's total share capital, to repay stock pledge financing loans [1] - New Hongze's Vice Chairman Meng Xue voluntarily waived his salary, including a basic annual salary of 1.07 million yuan, to focus on the company's strategic decisions and long-term development [2] - Guangqi Technology's subsidiary signed contracts totaling 264 million yuan for the mass production of metamaterials with four clients, with expected delivery by December 31, 2026 [3] Group 2 - Zhuhai Ming Technology's subsidiary received an allocation of 66,900 H-shares from Zhipu, amounting to 7.77 million Hong Kong dollars [4] - Chengdi Xiangjiang announced that the revenue from the construction of two data center buildings will decrease by approximately 1.09 billion yuan due to changes in business conditions [5] - Siquan New Materials' shareholder Wu Pan plans to reduce his holdings by up to 1.79% of the company's shares due to personal funding needs [6] Group 3 - Zhenxin Technology's subsidiary was banned from participating in procurement activities in the Western Theater for three years due to collusion in bidding [8] - Xinlitai's innovative drug SAL0145 injection clinical trial application has been accepted by the National Medical Products Administration, targeting MASH treatment [9] - Hengrui Medicine's innovative drug Ruira Fup α injection has been approved for market launch, with no similar products approved domestically or internationally [10] Group 4 - Baoneng New Energy's actual controller was fined 12 million yuan and had illegal gains of 25.54 million yuan confiscated due to violations of information disclosure [11] - Beidou Star Communication announced that several directors and executives plan to reduce their holdings by a total of 0.012% of the company's shares due to personal funding needs [12] - Pulit announced that its LCP film technology has a high barrier to entry and is the only domestic company to achieve breakthroughs in this technology, with ongoing clinical trials for brain-machine interface applications [13]